| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.32B | 9.83 | 70.21 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 728.57M | 4.30 | 11.32 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 944.78M | 2.38 | -1.86 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 604.8M | 7.71 | -2.51 | -117.82% | 0.18 | |||
| IMNMImmunome, Inc. | 2.29B | 20.76 | -4.15 | -35.5% | -23.01% | -84.4% | 0.03 | |
| NKTRNektar Therapeutics | 734.13M | 36.09 | -4.16 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IBRXImmunityBio, Inc. | 2.97B | 3.02 | -4.87 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.93B | 19.04 | -6.61 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 5.2M | 2.23M | 6.59M |
| Revenue Growth % | - | - | - | - | -0.57% | 1.95% |
| Cost of Goods Sold | 249K | 1.75M | 4.58M | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -249K | -1.75M | -4.58M | 5.2M | 2.23M | 6.59M |
| Gross Margin % | - | - | - | 1% | 1% | 1% |
| Gross Profit Growth % | - | -6.04% | -1.61% | 2.13% | -0.57% | 1.95% |
| Operating Expenses | 19.78M | 47.42M | 90.3M | 139.03M | 148.78M | 144.73M |
| OpEx % of Revenue | - | - | - | 26.74% | 66.57% | 21.96% |
| Selling, General & Admin | 5.52M | 7.74M | 14.65M | 31.86M | 34.71M | 33.16M |
| SG&A % of Revenue | - | - | - | 6.13% | 15.53% | 5.03% |
| Research & Development | 14.27M | 39.68M | 75.65M | 97.17M | 92.71M | 107.24M |
| R&D % of Revenue | - | - | - | 18.69% | 41.48% | 16.28% |
| Other Operating Expenses | 0 | 0 | 0 | 10M | 21.36M | 4.33M |
| Operating Income | -20.03M | -49.18M | -94.88M | -133.83M | -146.55M | -138.14M |
| Operating Margin % | - | - | - | -25.74% | -65.57% | -20.96% |
| Operating Income Growth % | - | -1.45% | -0.93% | -0.41% | -0.1% | 0.06% |
| EBITDA | -19.78M | -47.42M | -90.3M | -125.39M | -133.5M | -124.83M |
| EBITDA Margin % | - | - | - | -24.12% | -59.73% | -18.95% |
| EBITDA Growth % | - | -1.4% | -0.9% | -0.39% | -0.06% | 0.06% |
| D&A (Non-Cash Add-back) | 249K | 1.75M | 4.58M | 8.44M | 13.04M | 13.3M |
| EBIT | -244.77M | -53.19M | -94.51M | -129.64M | -134.25M | -124.78M |
| Net Interest Income | 1.21M | 323K | -377K | 2.99M | 12.14M | 13.01M |
| Interest Income | 1.21M | 704K | 898K | 2.99M | 12.68M | 13.01M |
| Interest Expense | 0 | 381K | 1.27M | 0 | 540K | 0 |
| Other Income/Expense | -224.74M | -4.4M | -898K | 2.99M | 11.75M | 13.36M |
| Pretax Income | -244.77M | -53.58M | -95.78M | -130.84M | -134.79M | -124.78M |
| Pretax Margin % | - | - | - | -25.17% | -60.31% | -18.94% |
| Income Tax | 0 | 0 | 43K | 91K | 1.88M | 1.79M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1.01% | 1.01% |
| Net Income | -244.77M | -53.58M | -95.82M | -130.93M | -136.67M | -126.57M |
| Net Margin % | - | - | - | -25.18% | -61.15% | -19.21% |
| Net Income Growth % | - | 0.78% | -0.79% | -0.37% | -0.04% | 0.07% |
| Net Income (Continuing) | -244.77M | -53.58M | -95.82M | -130.93M | -136.67M | -126.57M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.49 | -1.00 | -1.74 | -2.27 | -2.30 | -1.61 |
| EPS Growth % | - | 0.78% | -0.74% | -0.3% | -0.01% | 0.3% |
| EPS (Basic) | -4.49 | -1.00 | -1.74 | -2.27 | -2.30 | -1.61 |
| Diluted Shares Outstanding | 54.82M | 54.82M | 55.01M | 57.76M | 59.31M | 78.65M |
| Basic Shares Outstanding | 54.82M | 54.82M | 55.01M | 57.76M | 59.31M | 78.65M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 84.12M | 78.8M | 228.15M | 319.72M | 176.99M | 194.05M |
| Cash & Short-Term Investments | 81.54M | 75.75M | 222.88M | 315.5M | 172.74M | 189.29M |
| Cash Only | 44.06M | 27.21M | 56.45M | 84.27M | 47.32M | 58.44M |
| Short-Term Investments | 37.48M | 48.54M | 166.43M | 231.23M | 125.41M | 130.85M |
| Accounts Receivable | 123K | 908K | 250K | 780K | 665K | 1.52M |
| Days Sales Outstanding | - | - | - | 54.76 | 108.6 | 84.2 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 320K | 1.8M | 2.79M | 462K | 1.78M | 860K |
| Total Non-Current Assets | 6.77M | 27.98M | 209.22M | 166.82M | 183.7M | 159.16M |
| Property, Plant & Equipment | 2.49M | 24.78M | 69.82M | 111.73M | 92.08M | 90.85M |
| Fixed Asset Turnover | - | - | - | 0.05x | 0.02x | 0.07x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 9.39M | 0 | 0 | 0 | 34.2M |
| Long-Term Investments | 4.08M | 1.05M | 135.91M | 51.85M | 91.08M | 30.82M |
| Other Non-Current Assets | 206K | -7.24M | 3.49M | 3.24M | 541K | 3.3M |
| Total Assets | 90.9M | 106.78M | 437.38M | 486.54M | 360.69M | 353.22M |
| Asset Turnover | - | - | - | 0.01x | 0.01x | 0.02x |
| Asset Growth % | - | 0.17% | 3.1% | 0.11% | -0.26% | -0.02% |
| Total Current Liabilities | 2.99M | 12.11M | 15.65M | 29.82M | 17.85M | 129.78M |
| Accounts Payable | 1.55M | 8.08M | 7.6M | 5.45M | 2.74M | 3.08M |
| Days Payables Outstanding | 2.27K | 1.68K | 605.09 | - | - | - |
| Short-Term Debt | 0 | 0 | 1.04M | 6.5M | 1.51M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 1000K | 1000K | 1000K |
| Other Current Liabilities | 53K | 52K | 1.08M | 3.17M | 2.72M | 82K |
| Current Ratio | 28.10x | 6.51x | 14.57x | 10.72x | 9.92x | 1.50x |
| Quick Ratio | 28.10x | 6.51x | 14.57x | 10.72x | 9.92x | 1.50x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 179.76M | 201.08M | 25.48M | 153.99M | 158.09M | 62.07M |
| Long-Term Debt | 0 | 9.64M | 8.9M | 3.74M | 0 | 0 |
| Capital Lease Obligations | 0 | 11.68M | 14.56M | 38.7M | 46.66M | 48.96M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 4.37M |
| Other Non-Current Liabilities | 179.76M | 179.76M | 2.02M | 718K | 56K | 8.74M |
| Total Liabilities | 182.75M | 213.19M | 41.14M | 183.81M | 175.94M | 191.85M |
| Total Debt | 0 | 21.55M | 25.12M | 49.41M | 48.17M | 53.83M |
| Net Debt | -44.06M | -5.66M | -31.33M | -34.85M | 847K | -4.61M |
| Debt / Equity | - | - | 0.06x | 0.16x | 0.26x | 0.33x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | -129.07x | -74.42x | - | -271.38x | - |
| Total Equity | -91.86M | -106.41M | 396.24M | 302.74M | 184.75M | 161.36M |
| Equity Growth % | - | -0.16% | 4.72% | -0.24% | -0.39% | -0.13% |
| Book Value per Share | -1.68 | -1.94 | 7.20 | 5.24 | 3.11 | 2.05 |
| Total Shareholders' Equity | -91.86M | -106.41M | 396.24M | 302.74M | 184.75M | 161.36M |
| Common Stock | 1K | 1K | 5K | 6K | 6K | 9K |
| Retained Earnings | -238.77M | -292.34M | -388.17M | -519.1M | -655.77M | -782.34M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -3K | -3K | -650K | -2.46M | 108K | 324K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -16.17M | -41.27M | -89M | 14.05M | -88.35M | -110.14M |
| Operating CF Margin % | - | - | - | 2.7% | -39.53% | -16.71% |
| Operating CF Growth % | - | -1.55% | -1.16% | 1.16% | -7.29% | -0.25% |
| Net Income | -244.77M | -53.58M | -95.82M | -130.93M | -136.67M | -126.57M |
| Depreciation & Amortization | 249K | 1.4M | 3.75M | 8.44M | 13.04M | 13.3M |
| Stock-Based Compensation | 147K | 876K | 4.66M | 10.67M | 14.62M | 12.69M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 870K |
| Other Non-Cash Items | 225.95M | 5.17M | 1.21M | 1.93M | 11.28M | -1.15M |
| Working Capital Changes | 2.26M | 4.86M | -2.8M | 123.94M | 9.38M | -9.28M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.23M | 2.06M | -1.85M | -4.79M | -2.36M | -1.47M |
| Cash from Investing | -19.83M | -22.76M | -298.34M | -13.13M | 61.13M | 47.48M |
| Capital Expenditures | -2.46M | -9.82M | -44.97M | -30.6M | -13.74M | -154K |
| CapEx % of Revenue | - | - | - | 5.89% | 6.15% | 0.02% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 24.17M | -4.72M | 0 | 238.22M | 0 | 0 |
| Cash from Financing | 74.84M | 47.69M | 417.77M | 27.16M | -9.72M | 74.56M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | 37.96M | 36.53M | 0 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -18.63M | -51.09M | -133.97M | -16.55M | -102.08M | -110.29M |
| FCF Margin % | - | - | - | -3.18% | -45.68% | -16.74% |
| FCF Growth % | - | -1.74% | -1.62% | 0.88% | -5.17% | -0.08% |
| FCF per Share | -0.34 | -0.93 | -2.44 | -0.29 | -1.72 | -1.40 |
| FCF Conversion (FCF/Net Income) | 0.07x | 0.77x | 0.93x | -0.11x | 0.65x | 0.87x |
| Interest Paid | 0 | 0 | 0 | 1.1M | 586K | 0 |
| Taxes Paid | 0 | 207K | 983K | 1.1M | 3.11M | 501K |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -66.13% | -37.46% | -56.07% | -73.14% |
| Return on Invested Capital (ROIC) | - | - | -56.29% | -31.72% | -48.47% | -60.52% |
| Gross Margin | - | - | - | 100% | 100% | 100% |
| Net Margin | - | - | - | -2518.41% | -6115.12% | -1920.87% |
| Debt / Equity | - | - | 0.06x | 0.16x | 0.26x | 0.33x |
| Interest Coverage | - | -129.07x | -74.42x | - | -271.38x | - |
| FCF Conversion | 0.07x | 0.77x | 0.93x | -0.11x | 0.65x | 0.87x |
| Revenue Growth | - | - | - | - | -57.01% | 194.81% |
Century Therapeutics, Inc. (IPSC) reported $113.3M in revenue for fiscal year 2024.
Century Therapeutics, Inc. (IPSC) grew revenue by 194.8% over the past year. This is strong growth.
Century Therapeutics, Inc. (IPSC) reported a net loss of $26.5M for fiscal year 2024.
Century Therapeutics, Inc. (IPSC) has a return on equity (ROE) of -73.1%. Negative ROE indicates the company is unprofitable.
Century Therapeutics, Inc. (IPSC) had negative free cash flow of $112.7M in fiscal year 2024, likely due to heavy capital investments.